Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott Antonia

Showing results (1-10 of 82) with videos related to

Pageof 9
Sort By:
Expert Opinion on Investigational Drugs|April 1, 2003
Novel therapies for renal cell carcinoma--an updateMayer Fishman, Scott Antonia
Clinics in Chest Medicine|May 14, 2020
Breaking the Impasse: Advances in Treatment of Small Cell Lung CancerAndreas Saltos, Scott Antonia
Lancet (London, England)|February 28, 2004
Specific antitumour vaccine for renal cancerMayer Fishman, Scott Antonia
Journal of the National Cancer Institute|November 21, 2017
PD-L1 Antibodies for EBV-Positive Gastric Cancer, Going Beyond PD-L1 Expression and Microsatellite InstabilityKhaldoun Almhanna, Scott Antonia
Plos One|February 20, 2014
PD-L1 expression is increased in a subset of basal type breast cancer cellsHatem Soliman, Farah Khalil, Scott Antonia
Current Oncology Reports|August 3, 2021
Immune Checkpoint Inhibitors in the AgedJames Isaacs, Scott Antonia, Jeffrey Clarke
Cancer Immunology, Immunotherapy : CII|May 20, 2008
Combined modality immunotherapy and chemotherapy: a new perspectiveRupal Ramakrishnan, Scott Antonia, Dmitry I Gabrilovich
Cancer Chemotherapy and Pharmacology|August 22, 2009
Hepatic portal venous gas in a patient with metastatic non-small cell lung cancer on bevacizumab therapy: a case report and review of the literatureJose Ortega, J Michael Hayes, Scott Antonia
Cancer Journal (Sudbury, Mass.)|August 10, 2010
Indoleamine 2,3-dioxygenase: is it an immune suppressor?Hatem Soliman, Melanie Mediavilla-Varela, Scott Antonia
Cancer Management and Research|May 16, 2018
Durvalumab: a potential maintenance therapy in surgery-ineligible non-small-cell lung cancerMichael R Shafique, Lary A Robinson, Scott Antonia
Pageof 9

Showing results (1-10 of 82) with videos related to

Sort By:
Pageof 9
Expert Opinion on Investigational Drugs|April 1, 2003
Novel therapies for renal cell carcinoma--an updateMayer Fishman, Scott Antonia
Clinics in Chest Medicine|May 14, 2020
Breaking the Impasse: Advances in Treatment of Small Cell Lung CancerAndreas Saltos, Scott Antonia
Lancet (London, England)|February 28, 2004
Specific antitumour vaccine for renal cancerMayer Fishman, Scott Antonia
Journal of the National Cancer Institute|November 21, 2017
PD-L1 Antibodies for EBV-Positive Gastric Cancer, Going Beyond PD-L1 Expression and Microsatellite InstabilityKhaldoun Almhanna, Scott Antonia
Plos One|February 20, 2014
PD-L1 expression is increased in a subset of basal type breast cancer cellsHatem Soliman, Farah Khalil, Scott Antonia
Current Oncology Reports|August 3, 2021
Immune Checkpoint Inhibitors in the AgedJames Isaacs, Scott Antonia, Jeffrey Clarke
Cancer Immunology, Immunotherapy : CII|May 20, 2008
Combined modality immunotherapy and chemotherapy: a new perspectiveRupal Ramakrishnan, Scott Antonia, Dmitry I Gabrilovich
Cancer Chemotherapy and Pharmacology|August 22, 2009
Hepatic portal venous gas in a patient with metastatic non-small cell lung cancer on bevacizumab therapy: a case report and review of the literatureJose Ortega, J Michael Hayes, Scott Antonia
Cancer Journal (Sudbury, Mass.)|August 10, 2010
Indoleamine 2,3-dioxygenase: is it an immune suppressor?Hatem Soliman, Melanie Mediavilla-Varela, Scott Antonia
Cancer Management and Research|May 16, 2018
Durvalumab: a potential maintenance therapy in surgery-ineligible non-small-cell lung cancerMichael R Shafique, Lary A Robinson, Scott Antonia
Pageof 9